560 related articles for article (PubMed ID: 25496303)
1. A blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and ciclosporin for the control of atopic dermatitis in client-owned dogs.
Little PR; King VL; Davis KR; Cosgrove SB; Stegemann MR
Vet Dermatol; 2015 Feb; 26(1):23-30, e7-8. PubMed ID: 25496303
[TBL] [Abstract][Full Text] [Related]
2. A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel®) in client-owned dogs with atopic dermatitis.
Cosgrove SB; Wren JA; Cleaver DM; Walsh KF; Follis SI; King VI; Tena JK; Stegemann MR
Vet Dermatol; 2013 Dec; 24(6):587-97, e141-2. PubMed ID: 24581322
[TBL] [Abstract][Full Text] [Related]
3. Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life.
Cosgrove SB; Cleaver DM; King VL; Gilmer AR; Daniels AE; Wren JA; Stegemann MR
Vet Dermatol; 2015 Jun; 26(3):171-9, e35. PubMed ID: 25688708
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of oclacitinib (Apoquel®) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs in Australia.
Gadeyne C; Little P; King VL; Edwards N; Davis K; Stegemann MR
Vet Dermatol; 2014 Dec; 25(6):512-8, e86. PubMed ID: 25109820
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis.
Cosgrove SB; Wren JA; Cleaver DM; Martin DD; Walsh KF; Harfst JA; Follis SL; King VL; Boucher JF; Stegemann MR
Vet Dermatol; 2013 Oct; 24(5):479-e114. PubMed ID: 23829933
[TBL] [Abstract][Full Text] [Related]
6. Comparable efficacy of a topical 0.0584% hydrocortisone aceponate spray and oral ciclosporin in treating canine atopic dermatitis.
Nuttall TJ; McEwan NA; Bensignor E; Cornegliani L; Löwenstein C; Rème CA
Vet Dermatol; 2012 Feb; 23(1):4-10, e1-2. PubMed ID: 21718368
[TBL] [Abstract][Full Text] [Related]
7. The frequency of urinary tract infection and subclinical bacteriuria in dogs with allergic dermatitis treated with oclacitinib: a prospective study.
Simpson AC; Schissler JR; Rosychuk RAW; Moore AR
Vet Dermatol; 2017 Oct; 28(5):485-e113. PubMed ID: 28513001
[TBL] [Abstract][Full Text] [Related]
8. Comparison of various treatment options for canine atopic dermatitis: a blinded, randomized, controlled study in a colony of research atopic beagle dogs.
Marsella R; Ahrens K; Wilkes R; Trujillo A; Dorr M
Vet Dermatol; 2020 Aug; 31(4):284-e69. PubMed ID: 32301565
[TBL] [Abstract][Full Text] [Related]
9. A blinded, randomized clinical trial evaluating the efficacy and safety of lokivetmab compared to ciclosporin in client-owned dogs with atopic dermatitis.
Moyaert H; Van Brussel L; Borowski S; Escalada M; Mahabir SP; Walters RR; Stegemann MR
Vet Dermatol; 2017 Dec; 28(6):593-e145. PubMed ID: 28906040
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of 0.0584% hydrocortisone aceponate topical spray and systemic oclacitinib combination therapy in dogs with atopic dermatitis: a randomized, double-blinded, placebo-controlled trial.
Takahashi J; Kanda S; Imanishi I; Hisano T; Fukamachi T; Taguchi N; Momiyama S; Nishiyama S; Motegi T; Iyori K
Vet Dermatol; 2021 Apr; 32(2):119-e25. PubMed ID: 33185330
[TBL] [Abstract][Full Text] [Related]
11. Cyclosporine decreases skin lesions and pruritus in dogs with atopic dermatitis: a blinded randomized prednisolone-controlled trial.
Olivry T; Rivierre C; Jackson HA; Murphy KM; Davidson G; Sousa CA
Vet Dermatol; 2002 Apr; 13(2):77-87. PubMed ID: 11972891
[TBL] [Abstract][Full Text] [Related]
12. Repeated oral dose tolerance in dogs treated concomitantly with ciclosporin and oclacitinib for three weeks.
Panteri A; Strehlau G; Helbig R; Prost C; Doucette K
Vet Dermatol; 2016 Feb; 27(1):22-e7. PubMed ID: 26660461
[TBL] [Abstract][Full Text] [Related]
13. A blinded, randomized, placebo-controlled, dose determination trial of lokivetmab (ZTS-00103289), a caninized, anti-canine IL-31 monoclonal antibody in client owned dogs with atopic dermatitis.
Michels GM; Ramsey DS; Walsh KF; Martinon OM; Mahabir SP; Hoevers JD; Walters RR; Dunham SA
Vet Dermatol; 2016 Dec; 27(6):478-e129. PubMed ID: 27647569
[TBL] [Abstract][Full Text] [Related]
14. Oclacitinib in feline nonflea-, nonfood-induced hypersensitivity dermatitis: results of a small prospective pilot study of client-owned cats.
Ortalda C; Noli C; Colombo S; Borio S
Vet Dermatol; 2015 Aug; 26(4):235-e52. PubMed ID: 25940959
[TBL] [Abstract][Full Text] [Related]
15. A randomised, double-blinded, controlled trial to determine the efficacy of combined therapy of oclacitinib and marine oil extract PCSO-524 in dogs with atopic dermatitis.
Nishiyama T; Kusakabe M; Imanishi I; Hisano T; Fukamachi T; Taguchi N; Iyori K; Hsiao YH
Vet Dermatol; 2023 Dec; 34(6):523-531. PubMed ID: 37485602
[TBL] [Abstract][Full Text] [Related]
16. A randomised controlled trial testing the rebound-preventing benefit of four days of prednisolone during the induction of oclacitinib therapy in dogs with atopic dermatitis.
Olivry T; Lokianskiene V; Blanco A; Mestre PD; Bergvall K; Beco L
Vet Dermatol; 2023 Apr; 34(2):99-106. PubMed ID: 36330780
[TBL] [Abstract][Full Text] [Related]
17. Pilot evaluation of Enterococcus faecium SF68 as adjunctive therapy for oclacitinib-responsive adult atopic dermatitis in dogs.
Yamazaki C; Rosenkrantz W; Griffin C
J Small Anim Pract; 2019 Aug; 60(8):499-506. PubMed ID: 31257599
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of a 0.0584% hydrocortisone aceponate spray in the management of canine atopic dermatitis: a randomised, double blind, placebo-controlled trial.
Nuttall T; Mueller R; Bensignor E; Verde M; Noli C; Schmidt V; Rème C
Vet Dermatol; 2009 Jun; 20(3):191-8. PubMed ID: 19374721
[TBL] [Abstract][Full Text] [Related]
19. Clinical trial evaluating the efficacy and safety of cyclosporine in dogs with atopic dermatitis.
Steffan J; Parks C; Seewald W;
J Am Vet Med Assoc; 2005 Jun; 226(11):1855-63. PubMed ID: 15934253
[TBL] [Abstract][Full Text] [Related]
20. A pilot study on the effect of oclacitinib on epicutaneous sensitization and transepidermal water loss in a colony of atopic beagle dogs.
Marsella R; Ahrens K
Vet Dermatol; 2018 Oct; 29(5):439-e146. PubMed ID: 29926994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
